Primary sclerosing cholangitis – a comprehensive review

Journal of Hepatology

Volumn 67, Issue 6, 2017, Pages 1298-1323

  Karlsen, Tom H ^a,b   Folseraas, Trine ^a   Thorburn, Douglas ^c,d   Vesterhus, Mette ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholangiocarcinoma; IgG4 associated cholangitis; Primary sclerosing cholangitis

Indexed keywords

IMMUNOGLOBULIN G4;

AUTOIMMUNE HEPATITIS; BACTERIAL CHOLANGITIS; BILE DUCT CARCINOMA; CAUSE OF DEATH; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN G4 ASSOCIATED SCLEROSING CHOLANGITIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NON INVASIVE PROCEDURE; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SCLEROSING CHOLANGITIS; THERAPY; BIOPSY; GENETIC PREDISPOSITION; GENETICS; LIVER; PATHOLOGY; QUALITY OF LIFE;

BIOPSY; CHOLANGITIS, SCLEROSING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; LIVER TRANSPLANTATION; QUALITY OF LIFE;

EID: 85032190987     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.07.022     Document Type: Review

References (264)

1. Thorpe, M.E., Scheuer, P.J., Sherlock, S., Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut 8 (1967), 435–448.
2. Warren, K.W., Athanassiades, S., Monge, J.I., Primary sclerosing cholangitis. A study of forty-two cases. Am J Surg 111 (1966), 23–38.
3. Smith, M.P., Loe, R.H., Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 110 (1965), 239–246.
4. Schrumpf, E., Elgjo, K., Fausa, O., Gjone, E., Kolmannskog, F., Ritland, S., Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 15 (1980), 689–697.
5. Chapman, R.W., Arborgh, B.A., Rhodes, J.M., Summerfield, J.A., Dick, R., Scheuer, P.J., et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21 (1980), 870–877.
6. Wiesner, R.H., LaRusso, N.F., Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 79 (1980), 200–206.
7. Wee, A., Ludwig, J., Coffey, R.J. Jr., LaRusso, N.F., Wiesner, R.H., Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 16 (1985), 719–726.
8. Broome, U., Lindberg, G., Lofberg, R., Primary sclerosing cholangitis in ulcerative colitis–a risk factor for the development of dysplasia and DNA aneuploidy?. Gastroenterology 102 (1992), 1877–1880.
9. Wee, A., Ludwig, J., Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?. Ann Intern Med 102 (1985), 581–587.
10. Mendes, F.D., Jorgensen, R., Keach, J., Katzmann, J.A., Smyrk, T., Donlinger, J., et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 101 (2006), 2070–2075.
11. Berntsen, N.L., Klingenberg, O., Juran, B.D., Benito de Valle, M., Lindkvist, B., Lazaridis, K.N., et al. Haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis. Gastroenterology 148 (2015), 924–927 e922.
12. Siqueira, E., Schoen, R.E., Silverman, W., Martin, J., Rabinovitz, M., Weissfeld, J.L., et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 56 (2002), 40–47.
13. Perdigoto, R., Carpenter, H.A., Czaja, A.J., Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 14 (1992), 325–331.
14. Aadland, E., Schrumpf, E., Fausa, O., Elgjo, K., Heilo, A., Aakhus, T., et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 22 (1987), 655–664.
15. National Institutes of Health Consensus Development Conference Statement: liver transplantation–June 20-23, 1983. Hepatology 4 (1984), 107s–110s.
16. Lerut, J., Demetris, A.J., Stieber, A.C., Marsh, J.W., Gordon, R.D., Esquivel, C.O., et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection?. Transpl Int 1 (1988), 127–130.
17. Beuers, U., Spengler, U., Kruis, W., Aydemir, U., Wiebecke, B., Heldwein, W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (1992), 707–714.
18. Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K., Wagenaar, E., van Deemter, L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 (1993), 451–462.
19. Hohenester, S., Wenniger, L.M., Paulusma, C.C., van Vliet, S.J., Jefferson, D.M., Elferink, R.P., et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55 (2012), 173–183.
20. Karlsen, T.H., Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love?. Gut 65 (2016), 1579–1581.
21. Lichtman, S.N., Sartor, R.B., Keku, J., Schwab, J.H., Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 98 (1990), 414–423.
22. Terjung, B., Soehne, J., Lechtenberg, B., Gottwein, J., Muennich, M., Herzog, V., et al. P-ANCA in autoimmune liver disorders recognize human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59 (2010), 808–816.
23. Grant, A.J., Lalor, P.F., Hubscher, S.G., Briskin, M., Adams, D.H., MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33 (2001), 1065–1072.
24. Rossen, N.G., Fuentes, S., Boonstra, K., D'Haens, G.R., Heilig, H.G., Zoetendal, E.G., et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 9 (2015), 342–348.
25. Molodecky, N.A., Myers, R.P., Barkema, H.W., Quan, H., Kaplan, G.G., Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population-based study. Liver Int 31 (2011), 712–720.
26. Molodecky, N.A., Kareemi, H., Parab, R., Barkema, H.W., Quan, H., Myers, R.P., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 53 (2011), 1590–1599.
27. Jepsen, P., Gronbaek, L., Vilstrup, H., Worldwide incidence of autoimmune liver disease. Dig Dis 33 (2015), 2–12.
28. Tanaka, A., Takikawa, H., Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun 46 (2013), 35–40.
29. Kaplan, G.G., Laupland, K.B., Butzner, D., Urbanski, S.J., Lee, S.S., The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 102 (2007), 1042–1049.
30. Deneau, M., Jensen, M.K., Holmen, J., Williams, M.S., Book, L.S., Guthery, S.L., Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 58 (2013), 1392–1400.
31. Bambha, K., Kim, W.R., Talwalkar, J., Torgerson, H., Benson, J.T., Therneau, T.M., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125 (2003), 1364–1369.
32. Escorsell, A., Pares, A., Rodes, J., Solis-Herruzo, J.A., Miras, M., de la Morena, E., Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 21 (1994), 787–791.
33. Lindkvist, B., Benito de Valle, M., Gullberg, B., Bjornsson, E., Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52 (2010), 571–577.
34. Boonstra, K., Weersma, R.K., van Erpecum, K.J., Rauws, E.A., Spanier, B.W., Poen, A.C., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58 (2013), 2045–2055.
35. Bach, J.F., Infections and autoimmune diseases. J Autoimmun 25 (2005), 74–80.
36. Saarinen, S., Olerup, O., Broome, U., Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 95 (2000), 3195–3199.
37. Joo, M., Abreu-e-Lima, P., Farraye, F., Smith, T., Swaroop, P., Gardner, L., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 33 (2009), 854–862.
38. Riley, T.R., Schoen, R.E., Lee, R.G., Rakela, J., A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 92 (1997), 279–282.
39. Befeler, A.S., Lissoos, T.W., Schiano, T.D., Conjeevaram, H., Dasgupta, K.A., Millis, J.M., et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 65 (1998), 393–396.
40. Garioud, A., Seksik, P., Chretien, Y., Corphechot, C., Poupon, R., Poupon, R.E., et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol 22 (2010), 842–847.
41. Ataseven, H., Parlak, E., Yuksel, I., Basar, O., Ertugrul, I., Sasmaz, N., et al. Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis. Hepatobiliary Pancreat Dis Int 8 (2009), 312–315.
42. Hadizadeh, M., Abedi, S.H., Malekpour, H., Radinnia, E., Jabbehdari, S., Padashi, M., et al. Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran. Arab J Gastroenterol 17 (2016), 17–19.
43. Tanaka, A., Tazuma, S., Okazaki, K., Tsubouchi, H., Inui, K., Takikawa, H., Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 21 (2014), 43–50.
44. Tanaka, A., Tazuma, S., Okazaki, K., Tsubouchi, H., Inui, K., Takikawa, H., Clinical profiles of patients with primary sclerosing cholangitis in the elderly. J Hepatobiliary Pancreat Sci 22 (2015), 230–236.
45. Boonstra, K., Culver, E.L., de Buy Wenniger, L.M., van Heerde, M.J., van Erpecum, K.J., Poen, A.C., et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 59 (2014), 1954–1963.
46. Lunder, A.K., Hov, J.R., Borthne, A., Gleditsch, J., Johannesen, G., Tveit, K., et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151 (2016), 660–669 e664.
47. Bungay, H.K., Buchel, O.C., Cummings, F., Travis, S.P.L., Chapman, R.W., Prevalence and determinants of primary sclerosing cholangitis in a cohort of patients with inflammatory bowel disease and normal liver function tests. Gut, 57, 2008, A107.
48. Weismuller, T.J., Trivedi, P.J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C.Y., et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152 (2017), 1975–1984 e1978.
49. Halliday, J.S., Djordjevic, J., Lust, M., Culver, E.L., Braden, B., Travis, S.P., et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 6 (2012), 174–181.
50. Takikawa, H., Takamori, Y., Tanaka, A., Kurihara, H., Nakanuma, Y., Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 29 (2004), 153–159.
51. Okolicsanyi, L., Fabris, L., Viaggi, S., Carulli, N., Podda, M., Ricci, G., Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 8 (1996), 685–691.
52. Boberg, K.M., Bergquist, A., Mitchell, S., Pares, A., Rosina, F., Broome, U., et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37 (2002), 1205–1211.
53. Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Loof, L., Danielsson, A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002), 321–327.
54. Burak, K., Angulo, P., Pasha, T.M., Egan, K., Petz, J., Lindor, K.D., Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99 (2004), 523–526.
55. Fevery, J., Verslype, C., Lai, G., Aerts, R., Van Steenbergen, W., Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 52 (2007), 3123–3135.
56. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
57. Chapman, R., Fevery, J., Kalloo, A., Nagorney, D.M., Boberg, K.M., Shneider, B., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51 (2010), 660–678.
58. Soetikno, R.M., Lin, O.S., Heidenreich, P.A., Young, H.S., Blackstone, M.O., Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56 (2002), 48–54.
59. European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol 66 (2017), 1265–1281.
60. Zenouzi, R., Weismuller, T.J., Hubener, P., Schulze, K., Bubenheim, M., Pannicke, N., et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 12 (2014), 1733–1738.
61. Said, K., Glaumann, H., Bergquist, A., Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 48 (2008), 598–605.
62. Brandt, D.J., MacCarty, R.L., Charboneau, J.W., LaRusso, N.F., Wiesner, R.H., Ludwig, J., Gallbladder disease in patients with primary sclerosing cholangitis. AJR Am J Roentgenol 150 (1988), 571–574.
63. Buckles, D.C., Lindor, K.D., Larusso, N.F., Petrovic, L.M., Gores, G.J., In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 97 (2002), 1138–1142.
64. Lewis, J.T., Talwalkar, J.A., Rosen, C.B., Smyrk, T.C., Abraham, S.C., Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 31 (2007), 907–913.
65. Eaton, J.E., Thackeray, E.W., Lindor, K.D., Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 107 (2012), 431–439.
66. Schwartz, S.I., Dale, W.A., Primary sclerosing cholangitis; review and report of six cases. AMA Arch Surg 77 (1958), 439–451.
67. Jeffrey, G.P., Reed, W.D., Carrello, S., Shilkin, K.B., Histological and immunohistochemical study of the gall bladder lesion in primary sclerosing cholangitis. Gut 32 (1991), 424–429.
68. Kaw, M., Silverman, W.B., Rabinovitz, M., Schade, R.R., Biliary tract calculi in primary sclerosing cholangitis. Am J Gastroenterol 90 (1995), 72–75.
69. Pokorny, C.S., McCaughan, G.W., Gallagher, N.D., Selby, W.S., Sclerosing cholangitis and biliary tract calculi–primary or secondary?. Gut 33 (1992), 1376–1380.
70. Karlsen, T.H., Schrumpf, E., Boberg, K.M., Gallbladder polyps in primary sclerosing cholangitis: not so benign. Curr Opin Gastroenterol 24 (2008), 395–399.
71. Bergquist, A., Montgomery, S.M., Bahmanyar, S., Olsson, R., Danielsson, A., Lindgren, S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 6 (2008), 939–943.
72. Karlsen, T.H., Melum, E., Franke, A., The utility of genome-wide association studies in hepatology. Hepatology 51 (2010), 1833–1842.
73. Ji, S.G., Juran, B.D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet 49 (2017), 269–273.
74. Ellinghaus, D., Jostins, L., Spain, S.L., Cortes, A., Bethune, J., Han, B., et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 48 (2016), 510–518.
75. Liu, J.Z., Hov, J.R., Folseraas, T., Ellinghaus, E., Rushbrook, S.M., Doncheva, N.T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45 (2013), 670–675.
76. Ellinghaus, D., Folseraas, T., Holm, K., Ellinghaus, E., Melum, E., Balschun, T., et al. Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58 (2013), 1074–1083.
77. Melum, E., Franke, A., Schramm, C., Weismuller, T.J., Gotthardt, D.N., Offner, F.A., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 43 (2011), 17–19.
78. Karlsen, T.H., Franke, A., Melum, E., Kaser, A., Hov, J.R., Balschun, T., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138 (2010), 1102–1111.
79. Folseraas, T., Melum, E., Rausch, P., Juran, B.D., Ellinghaus, E., Shiryaev, A., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 57 (2012), 366–375.
80. Srivastava, B., Mells, G.F., Cordell, H.J., Muriithi, A., Brown, M., Ellinghaus, E., et al. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol 47 (2012), 820–826.
81. Jiang, X., Karlsen, T.H., Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol 14 (2017), 279–295.
82. Farh, K.K., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518 (2015), 337–343.
83. Sebode, M., Peiseler, M., Franke, B., Schwinge, D., Schoknecht, T., Wortmann, F., et al. Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. J Hepatol 60 (2014), 1010–1016.
84. Liaskou, E., Jeffery, L.E., Trivedi, P.J., Reynolds, G.M., Suresh, S., Bruns, T., et al. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 147 (2014), 221–232 e227.
85. Naess, S., Lie, B.A., Melum, E., Olsson, M., Hov, J.R., Croucher, P.J., et al. Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population. PLoS One, 9, 2014, e114486.
86. Hov, J.R., Kosmoliaptsis, V., Traherne, J.A., Olsson, M., Boberg, K.M., Bergquist, A., et al. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology 53 (2011), 1967–1976.
87. O'Hara, S.P., Karlsen, T.H., LaRusso, N.F., Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?. Gut, 2017, 10.1136/gutjnl-2017-314249 [In press], pii: gutjnl-2017-314249.
88. Liaskou, E., Klemsdal Henriksen, E.K., Holm, K., Kaveh, F., Hamm, D., Fear, J., et al. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology 63 (2016), 1608–1619.
89. Das, K.M., Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J Gastroenterol Hepatol 19 (2004), S290–S294.
90. Grant, A.J., Lalor, P.F., Salmi, M., Jalkanen, S., Adams, D.H., Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359 (2002), 150–157.
91. Trivedi, P.J., Adams, D.H., Gut-liver immunity. J Hepatol 64 (2016), 1187–1189.
92. Whiteside, T.L., Lasky, S., Si, L., Van Thiel, D.H., Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 5 (1985), 468–474.
93. Ponsioen, C.Y., Kuiper, H., Ten Kate, F.J., van Milligen de Wit, M., van Deventer, S.J., Tytgat, G.N., Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 11 (1999), 769–774.
94. Oo, Y.H., Banz, V., Kavanagh, D., Liaskou, E., Withers, D.R., Humphreys, E., et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 57 (2012), 1044–1051.
95. Kamihira, T., Shimoda, S., Nakamura, M., Yokoyama, T., Takii, Y., Kawano, A., et al. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. Hepatology 41 (2005), 151–159.
96. Cameron, R.G., Blendis, L.M., Neuman, M.G., Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem 34 (2001), 195–201.
97. Demetris, A.J., Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 12 (2006), S68–S72.
98. Zweers, S.J., Shiryaev, A., Komuta, M., Vesterhus, M., Hov, J.R., Perugorria, M.J., et al. Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. Liver Int 36 (2016), 1370–1377.
99. Gauss, A., Sauer, P., Stiehl, A., Rupp, C., Krisam, J., Leopold, Y., et al. Evaluation of biliary calprotectin as a biomarker in primary sclerosing cholangitis. Medicine, 95, 2016, e3510.
100. Vesterhus, M., Holm, A., Hov, J.R., Nygard, S., Schrumpf, E., Melum, E., et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol 66 (2017), 1214–1222.
101. Fiorotto, R., Scirpo, R., Trauner, M., Fabris, L., Hoque, R., Spirli, C., Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice. Gastroenterology 141 (2011), 1498–1508 e1491–e1495.
102. Bjornsson, E., Cederborg, A., Akvist, A., Simren, M., Stotzer, P.O., Bjarnason, I., Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol 40 (2005), 1090–1094.
103. Mitro, N., Godio, C., De Fabiani, E., Scotti, E., Galmozzi, A., Gilardi, F., et al. Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis. Hepatology 46 (2007), 885–897.
104. Hov, J.R., Keitel, V., Laerdahl, J.K., Spomer, L., Ellinghaus, E., ElSharawy, A., et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One, 5, 2010, e12403.
105. Boyer, J.L., Bile formation and secretion. Compr Physiol 3 (2013), 1035–1078.
106. Beuers, U., Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3 (2006), 318–328.
107. Fickert, P., Pollheimer, M.J., Silbert, D., Moustafa, T., Halilbasic, E., Krones, E., et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 58 (2013), 1201–1208.
108. Fickert, P., Wagner, M., Marschall, H.U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130 (2006), 465–481.
109. Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H.U., Moustafa, T., Spirli, C., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 49 (2009), 1972–1981.
110. Sombetzki, M., Fuchs, C.D., Fickert, P., Osterreicher, C.H., Mueller, M., Claudel, T., et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 62 (2015), 871–878.
111. Beuers, U., Trauner, M., Jansen, P., Poupon, R., New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62 (2015), S25–S37.
112. Alvaro, D., Gigliozzi, A., Attili, A.F., Regulation and deregulation of cholangiocyte proliferation. J Hepatol 33 (2000), 333–340.
113. Carpino, G., Cardinale, V., Renzi, A., Hov, J.R., Berloco, P.B., Rossi, M., et al. Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis. J Hepatol 63 (2015), 1220–1228.
114. Mederacke, I., Hsu, C.C., Troeger, J.S., Huebener, P., Mu, X., Dapito, D.H., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun, 4, 2013, 2823.
115. Lemoinne, S., Cadoret, A., Rautou, P.E., El Mourabit, H., Ratziu, V., Corpechot, C., et al. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology 61 (2015), 1041–1055.
116. Kobayashi, S., Werneburg, N.W., Bronk, S.F., Kaufmann, S.H., Gores, G.J., Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128 (2005), 2054–2065.
117. Boulter, L., Guest, R.V., Kendall, T.J., Wilson, D.H., Wojtacha, D., Robson, A.J., et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest 125 (2015), 1269–1285.
118. Komichi, D., Tazuma, S., Nishioka, T., Hyogo, H., Chayama, K., Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med 39 (2005), 1418–1427.
119. Liu, R., Zhao, R., Zhou, X., Liang, X., Campbell, D.J., Zhang, X., et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 60 (2014), 908–918.
120. Lozano, E., Sanchez-Vicente, L., Monte, M.J., Herraez, E., Briz, O., Banales, J.M., et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res 12 (2014), 91–100.
121. Sampaziotis, F., Cardoso de Brito, M., Madrigal, P., Bertero, A., Saeb-Parsy, K., Soares, F.A., et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol 33 (2015), 845–852.
122. Fickert, P., Pollheimer, M.J., Beuers, U., Lackner, C., Hirschfield, G., Housset, C., et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 60 (2014), 1290–1303.
123. Tremaroli, V., Backhed, F., Functional interactions between the gut microbiota and host metabolism. Nature 489 (2012), 242–249.
124. Ridlon, J.M., Bajaj, J.S., The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sin B 5 (2015), 99–105.
125. Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
126. Wahlstrom, A., Kovatcheva-Datchary, P., Stahlman, M., Khan, M.T., Backhed, F., Marschall, H.U., Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res 58 (2017), 412–419.
127. Kevans, D., Tyler, A.D., Holm, K., Jorgensen, K.K., Vatn, M.H., Karlsen, T.H., et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 10 (2016), 330–337.
128. Kummen, M., Holm, K., Anmarkrud, J.A., Nygard, S., Vesterhus, M., Hoivik, M.L., et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66 (2017), 611–619.
129. Torres, J., Bao, X., Goel, A., Colombel, J.F., Pekow, J., Jabri, B., et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 43 (2016), 790–801.
130. Quraishi, M.N., Sergeant, M., Kay, G., Iqbal, T., Chan, J., Constantinidou, C., et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 66 (2017), 386–388.
131. Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65 (2016), 1681–1689.
132. Ruhlemann, M.C., Heinsen, F.A., Zenouzi, R., Lieb, W., Franke, A., Schramm, C., Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 66 (2017), 753–754.
133. Mikx, F.H., Van der Hoeven, J.S., Symbiosis of Streptococcus mutans and Veillonella alcalescens in mixed continuous cultures. Arch Oral Biol 20 (1975), 407–410.
134. Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
135. Maroni, L., Hohenester, S.D., van de Graaf, S.F., Tolenaars, D., van Lienden, K., Verheij, J., et al. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice. Hepatology 66 (2017), 542–554.
136. Tabibian, J.H., Talwalkar, J.A., Lindor, K.D., Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int, 2013, 2013, 389537.
137. Talwalkar, J.A., Angulo, P., Johnson, C.D., Petersen, B.T., Lindor, K.D., Cost-minimization analysis of MRC vs. ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 40 (2004), 39–45.
138. Dave, M., Elmunzer, B.J., Dwamena, B.A., Higgins, P.D., Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 256 (2010), 387–396.
139. Lennard-Jones, J.E., Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170 (1989), 2–6.
140. Truelove, S.C., Pena, A.S., Course and prognosis of Crohn's disease. Gut 17 (1976), 192–201.
141. Maillette de Buy Wenniger, L., Rauws, E.A., Beuers, U., What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree. Endoscopy 44 (2012), 66–73.
142. Doorenspleet, M.E., Hubers, L.M., Culver, E.L., Maillette de Buy Wenniger, L.J., Klarenbeek, P.L., Chapman, R.W., et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 64 (2016), 501–507.
143. Hart, P.A., Topazian, M.D., Witzig, T.E., Clain, J.E., Gleeson, F.C., Klebig, R.R., et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 62 (2013), 1607–1615.
144. Shiokawa, M., Kodama, Y., Kuriyama, K., Yoshimura, K., Tomono, T., Morita, T., et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut 65 (2016), 1322–1332.
145. Bjornsson, E., Small-duct primary sclerosing cholangitis. Curr Gastroenterol Rep 11 (2009), 37–41.
146. Naess, S., Bjornsson, E., Anmarkrud, J.A., Al Mamari, S., Juran, B.D., Lazaridis, K.N., et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int 34 (2014), 1488–1495.
147. Deneau, M.R., El-Matary, W., Valentino, P.L., Abdou, R., Alqoaer, K., Amin, M., et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology 66 (2017), 518–527.
148. Boberg, K.M., Chapman, R.W., Hirschfield, G.M., Lohse, A.W., Manns, M.P., Schrumpf, E., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 54 (2011), 374–385.
149. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 63 (2015), 971–1004.
150. Bergquist, A., Said, K., Broome, U., Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 42 (2007), 88–93.
151. Broome, U., Olsson, R., Loof, L., Bodemar, G., Hultcrantz, R., Danielsson, A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 (1996), 610–615.
152. Helzberg, J.H., Petersen, J.M., Boyer, J.L., Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 92 (1987), 1869–1875.
153. Wiesner, R.H., Grambsch, P.M., Dickson, E.R., Ludwig, J., MacCarty, R.L., Hunter, E.B., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10 (1989), 430–436.
154. Farrant, J.M., Hayllar, K.M., Wilkinson, M.L., Karani, J., Portmann, B.C., Westaby, D., et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100 (1991), 1710–1717.
155. Dickson, E.R., Murtaugh, P.A., Wiesner, R.H., Grambsch, P.M., Fleming, T.R., Ludwig, J., et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103 (1992), 1893–1901.
156. Boberg, K.M., Rocca, G., Egeland, T., Bergquist, A., Broome, U., Caballeria, L., et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 35 (2002), 652–657.
157. Lindor, K.D., Kowdley, K.V., Luketic, V.A., Harrison, M.E., McCashland, T., Befeler, A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50 (2009), 808–814.
158. Lammers, W.J., van Buuren, H.R., Hirschfield, G.M., Janssen, H.L., Invernizzi, P., Mason, A.L., et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147 (2014), 1338–1349 e1335; quiz e1315.
159. Stanich, P.P., Bjornsson, E., Gossard, A.A., Enders, F., Jorgensen, R., Lindor, K.D., Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 43 (2011), 309–313.
160. Al Mamari, S., Djordjevic, J., Halliday, J.S., Chapman, R.W., Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 58 (2013), 329–334.
161. Lindstrom, L., Hultcrantz, R., Boberg, K.M., Friis-Liby, I., Bergquist, A., Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 11 (2013), 841–846.
162. Rupp, C., Rossler, A., Halibasic, E., Sauer, P., Weiss, K.H., Friedrich, K., et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 40 (2014), 1292–1301.
163. de Vries, E.M., Wang, J., Leeflang, M.M., Boonstra, K., Weersma, R.K., Beuers, U.H., et al. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. Liver Int 36 (2016), 1867–1875.
164. Ponsioen, C.Y., Vrouenraets, S.M., Prawirodirdjo, W., Rajaram, R., Rauws, E.A., Mulder, C.J., et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51 (2002), 562–566.
165. Ni Mhuircheartaigh, J.M., Lee, K.S., Curry, M.P., Pedrosa, I., Mortele, K.J., Early peribiliary hyperenhancement on mri in patients with primary sclerosing cholangitis: significance and association with the mayo risk score. Abdom Radiol 42 (2017), 152–158.
166. Petrovic, B.D., Nikolaidis, P., Hammond, N.A., Martin, J.A., Petrovic, P.V., Desai, P.M., et al. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci 52 (2007), 3499–3506.
167. de Vries, E.M., Verheij, J., Hubscher, S.G., Leeflang, M.M., Boonstra, K., Beuers, U., et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol 63 (2015), 1212–1219.
168. de Vries, E.M., de Krijger, M., Farkkila, M., Arola, J., Schirmacher, P., Gotthardt, D., et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology 65 (2017), 907–919.
169. Olsson, R., Hagerstrand, I., Broome, U., Danielsson, A., Jarnerot, G., Loof, L., et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 48 (1995), 933–935.
170. Angulo, P., Larson, D.R., Therneau, T.M., LaRusso, N.F., Batts, K.P., Lindor, K.D., Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 94 (1999), 3310–3313.
171. Vesterhus, M., Hov, J.R., Holm, A., Schrumpf, E., Nygard, S., Godang, K., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 62 (2015), 188–197.
172. de Vries, E.M., Farkkila, M., Milkiewicz, P., Hov, J.R., Eksteen, B., Thorburn, D., et al. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int 37 (2017), 1554–1561.
173. Corpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 146 (2014), 970–979 e976.
174. Corpechot, C., El Naggar, A., Poujol-Robert, A., Ziol, M., Wendum, D., Chazouilleres, O., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43 (2006), 1118–1124.
175. Ehlken, H., Wroblewski, R., Corpechot, C., Arrive, L., Rieger, T., Hartl, J., et al. Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis. PLoS One, 11, 2016, e0164224.
176. Ponsioen, C.Y., Chapman, R.W., Chazouilleres, O., Hirschfield, G.M., Karlsen, T.H., Lohse, A.W., et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology 63 (2016), 1357–1367.
177. Ehlken, H., Lohse, A.W., Schramm, C., Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations. Gastroenterology 147 (2014), 542–543.
178. Attia, D., Pischke, S., Negm, A.A., Rifai, K., Manns, M.P., Gebel, M.J., et al. Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. Dig Liver Dis 46 (2014), 625–631.
179. Eaton, J.E., Dzyubak, B., Venkatesh, S.K., Smyrk, T.C., Gores, G.J., Ehman, R.L., et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol 31 (2016), 1184–1190.
180. 2016 PSsM. http://www.pscsupport.org.uk/sites/default/files/files/PSC%20Support%20Patient%20Survey%20Results(2).pdf).
181. Younossi, Z.M., Kiwi, M.L., Boparai, N., Price, L.L., Guyatt, G., Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 95 (2000), 497–502.
182. Gross, C.R., Malinchoc, M., Kim, W.R., Evans, R.W., Wiesner, R.H., Petz, J.L., et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 29 (1999), 356–364.
183. Bjornsson, E., Simren, M., Olsson, R., Chapman, R.W., Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 39 (2004), 961–968.
184. Haapamaki, J., Tenca, A., Sintonen, H., Barner-Rasmussen, N., Farkkila, M.A., Health-related quality of life among patients with primary sclerosing cholangitis. Liver Int 35 (2015), 2194–2201.
185. Raszeja-Wyszomirska, J., Wunsch, E., Krawczyk, M., Rigopoulou, E.I., Bogdanos, D., Milkiewicz, P., Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver Int 35 (2015), 1764–1771.
186. Dyson, J.K., Elsharkawy, A.M., Lamb, C.A., Al-Rifai, A., Newton, J.L., Jones, D.E., et al. Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver Int 35 (2015), 1633–1641.
187. Cheung, A.C., Patel, H., Meza-Cardona, J., Cino, M., Sockalingam, S., Hirschfield, G.M., Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci 61 (2016), 1692–1699.
188. Andersen, I.M., Fosby, B., Boberg, K.M., Clausen, O.P., Jebsen, P., Melum, E., et al. Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway. Transplant Direct, 1, 2015, e39.
189. Carbone, M., Bufton, S., Monaco, A., Griffiths, L., Jones, D.E., Neuberger, J.M., The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 59 (2013), 490–494.
190. Bilhartz, L.E., Gallstone disease and its complications. 6th ed., 1998, Saunders.
191. Lindor, K.D., Kowdley, K.V., Harrison, M.E., American College of G. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 110 (2015), 646–659 quiz 660.
192. Rudolph, G., Gotthardt, D., Kloters-Plachky, P., Kulaksiz, H., Rost, D., Stiehl, A., Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 51 (2009), 149–155.
193. Goldberg, D.S., Camp, A., Martinez-Camacho, A., Forman, L., Fortune, B., Reddy, K.R., Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl 19 (2013), 250–258.
194. Stiehl, A., Rudolph, G., Kloters-Plachky, P., Sauer, P., Walker, S., Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 36 (2002), 151–156.
195. Bjornsson, E., Lindqvist-Ottosson, J., Asztely, M., Olsson, R., Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99 (2004), 502–508.
196. Etzel, J.P., Eng, S.C., Ko, C.W., Lee, S.D., Saunders, M.D., Tung, B.Y., et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc 67 (2008), 643–648.
197. Ismail, S., Kylanpaa, L., Mustonen, H., Halttunen, J., Lindstrom, O., Jokelainen, K., et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 44 (2012), 1133–1138.
198. Bangarulingam, S.Y., Gossard, A.A., Petersen, B.T., Ott, B.J., Lindor, K.D., Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 104 (2009), 855–860.
199. Navaneethan, U., Jegadeesan, R., Nayak, S., Lourdusamy, V., Sanaka, M.R., Vargo, J.J., et al. ERCP-related adverse events in patients with primary sclerosing cholangitis. Gastrointest Endosc 81 (2015), 410–419.
200. van den Hazel, S.J., Wolfhagen, E.H., van Buuren, H.R., van de Meeberg, P.C., Van Leeuwen, D.J., Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 32 (2000), 779–782.
201. von Seth, E., Arnelo, U., Enochsson, L., Bergquist, A., Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography. Liver Int 35 (2015), 254–262.
202. Gotthardt, D.N., Rudolph, G., Kloters-Plachky, P., Kulaksiz, H., Stiehl, A., Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 71 (2010), 527–534.
203. Ponsioen, C.Y., Lam, K., van Milligen de Wit, A.W., Huibregtse, K., Tytgat, G.N., Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 94 (1999), 2403–2407.
204. Ponsioen, C., Arnelo, U., Bergquist, A., Rauws, E., Paulsen, V., Cantu, P., et al. Multicenter randomized trial comparing short-term stenting vs. balloon dilatation for dominant strictures in primary sclerosing cholangitis. J Hepatol 66 (2017), S1–S2.
205. Charatcharoenwitthaya, P., Enders, F.B., Halling, K.C., Lindor, K.D., Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48 (2008), 1106–1117.
206. Boberg, K.M., Lind, G.E., Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 25 (2011), 753–764.
207. Levy, C., Lymp, J., Angulo, P., Gores, G.J., Larusso, N., Lindor, K.D., The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 50 (2005), 1734–1740.
208. Wannhoff, A., Hov, J.R., Folseraas, T., Rupp, C., Friedrich, K., Anmarkrud, J.A., et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 59 (2013), 1278–1284.
209. Razumilava, N., Gores, G.J., Lindor, K.D., Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54 (2011), 1842–1852.
210. Sangfelt, P., Sundin, A., Wanders, A., Rasmussen, I., Karlson, B.M., Bergquist, A., et al. Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol 61 (2014), 1352–1357.
211. Navaneethan, U., Njei, B., Venkatesh, P.G., Lourdusamy, V., Sanaka, M.R., Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep 3 (2015), 209–215.
212. Arnelo, U., von Seth, E., Bergquist, A., Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy 47 (2015), 696–702.
213. Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J.J., Parsi, M.A., Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 79 (2014), 783–789.
214. Navaneethan, U., Njei, B., Venkatesh, P.G., Vargo, J.J., Parsi, M.A., Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 79 (2014), 943–950 e943.
215. Folseraas, T., Boberg, K.M., Cancer risk and surveillance in primary sclerosing cholangitis. Clin Liver Dis 20 (2016), 79–98.
216. Lewis, J.T., Talwalkar, J.A., Rosen, C.B., Smyrk, T.C., Abraham, S.C., Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 34 (2010), 27–34.
217. Nathan, H., Pawlik, T.M., Wolfgang, C.L., Choti, M.A., Cameron, J.L., Schulick, R.D., Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11 (2007), 1488–1496 [Discussion 1496–1487].
218. Rosen, C.B., Heimbach, J.K., Gores, G.J., Liver transplantation for cholangiocarcinoma. Transpl Int 23 (2010), 692–697.
219. Valle, J.W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25 (2014), 391–398.
220. Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer. N Engl J Med 362 (2010), 1273–1281.
221. Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103 (2010), 469–474.
222. Blechacz, B., Gores, G.J., Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48 (2008), 308–321.
223. Poropat, G., Giljaca, V., Stimac, D., Gluud, C., Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev, 2011, Cd003626.
224. Lazaridis, K.N., LaRusso, N.F., Primary sclerosing cholangitis. N Engl J Med 375 (2016), 1161–1170.
225. Gregorio, G.V., Portmann, B., Karani, J., Harrison, P., Donaldson, P.T., Vergani, D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 (2001), 544–553.
226. Bader, T.R., Beavers, K.L., Semelka, R.C., MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease. Radiology 226 (2003), 675–685.
227. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64 (2016), 433–485.
228. Goldberg, D., French, B., Thomasson, A., Reddy, K.R., Halpern, S.D., Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl 17 (2011), 1355–1363.
229. Weismuller, T.J., Fikatas, P., Schmidt, J., Barreiros, A.P., Otto, G., Beckebaum, S., et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany–limitations of the 'sickest first’-concept. Transpl Int 24 (2011), 91–99.
230. Klose, J., Klose, M.A., Metz, C., Lehner, F., Manns, M.P., Klempnauer, J., et al. Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era. Langenbecks Arch Surg 399 (2014), 1021–1029.
231. Barber, K., Blackwell, J., Collett, D., Neuberger, J., Life expectancy of adult liver allograft recipients in the UK. Gut 56 (2007), 279–282.
232. Joshi, D., Bjarnason, I., Belgaumkar, A., O'Grady, J., Suddle, A., Heneghan, M.A., et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 33 (2013), 53–61.
233. Goldberg, D.S., French, B., Thomasson, A., Reddy, K.R., Halpern, S.D., Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation 91 (2011), 1148–1152.
234. Goldberg, D.S., French, B., Abt, P.L., Olthoff, K., Shaked, A., Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology 60 (2014), 1717–1726.
235. Krzanicki, D., Sugavanam, A., Mallett, S., Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transpl 19 (2013), 852–861.
236. Pandanaboyana, S., Bell, R., Bartlett, A.J., McCall, J., Hidalgo, E., Meta-analysis of Duct-to-duct vs. Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 28 (2015), 485–491.
237. Fosby, B., Karlsen, T.H., Melum, E., Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 18 (2012), 1–15.
238. Ravikumar, R., Tsochatzis, E., Jose, S., Allison, M., Athale, A., Creamer, F., et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 63 (2015), 1139–1146.
239. Hildebrand, T., Pannicke, N., Dechene, A., Gotthardt, D.N., Kirchner, G., Reiter, F.P., et al. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transpl 22 (2016), 42–52.
240. Loftus, E.V. Jr., Harewood, G.C., Loftus, C.G., Tremaine, W.J., Harmsen, W.S., Zinsmeister, A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54 (2005), 91–96.
241. Kaminski, M.F., Hassan, C., Bisschops, R., Pohl, J., Pellise, M., Dekker, E., et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 46 (2014), 435–449.
242. Subramanian, V., Mannath, J., Ragunath, K., Hawkey, C.J., Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 33 (2011), 304–312.
243. Annese, V., Daperno, M., Rutter, M.D., Amiot, A., Bossuyt, P., East, J., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7 (2013), 982–1018.
244. de Vries, A.B., Janse, M., Blokzijl, H., Weersma, R.K., Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 21 (2015), 1956–1971.
245. Singh, S., Loftus, E.V. Jr., Talwalkar, J.A., Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 108 (2013), 1417–1425.
246. Guanabens, N., Pares, A., Management of osteoporosis in liver disease. Clin Res Hepatol Gastroenterol 35 (2011), 438–445.
247. Fickert, P., Hirschfield, G.M., Denk, G., Marschall, H.U., Altorjay, I., Farkkila, M., et al. NorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 67 (2017), 549–558.
248. Muir, A., Goodman, Z., Levy, C., Janssen, H., Montano-Loza, A., Bowlus, C., et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. J Hepatol, 66, 2017, S73.
249. Trivedi, P.J., Adams, D.H., Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 46 (2013), 97–111.
250. Hov, J.R., Boberg, K.M., Karlsen, T.H., Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 14 (2008), 3781–3791.
251. Trauner, M., Meier, P.J., Boyer, J.L., Molecular pathogenesis of cholestasis. N Engl J Med 339 (1998), 1217–1227.
252. Dutta, A.K., Khimji, A.K., Kresge, C., Bugde, A., Dougherty, M., Esser, V., et al. Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem 286 (2011), 766–776.
253. Keitel, V., Ullmer, C., Haussinger, D., The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem 391 (2010), 785–789.
254. Keitel, V., Cupisti, K., Ullmer, C., Knoefel, W.T., Kubitz, R., Haussinger, D., The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50 (2009), 861–870.
255. Xu, B., Broome, U., Ericzon, B.G., Sumitran-Holgersson, S., High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51 (2002), 120–127.
256. Boberg, K.M., Jebsen, P., Clausen, O.P., Foss, A., Aabakken, L., Schrumpf, E., Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 45 (2006), 568–574.
257. Kim, W.R., Therneau, T.M., Wiesner, R.H., Poterucha, J.J., Benson, J.T., Malinchoc, M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 (2000), 688–694.
258. Tischendorf, J.J., Hecker, H., Kruger, M., Manns, M.P., Meier, P.N., Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 102 (2007), 107–114.
259. Jendrek, S.T., Gotthardt, D., Nitzsche, T., Widmann, L., Korf, T., Michaels, M.A., et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 66 (2017), 137–144.
260. Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973), 646–649.
261. Kamath, P.S., Wiesner, R.H., Malinchoc, M., Kremers, W., Therneau, T.M., Kosberg, C.L., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001), 464–470.
262. Trivedi, P.J., Tickle, J., Vesterhus, M.N., Eddowes, P.J., Bruns, T., Vainio, J., et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut, 2017, 10.1136/gutjnl-2016-312354 [In press], pii: gutjnl-2016-312354.
263. Ehlken, H., Wroblewski, R., Corpechot, C., Arrive, L., Lezius, S., Hartl, J., et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut 65 (2016), 1230–1232.
264. Alberts, R., de Vries, E.M.G., Goode, E.C., Jiang, X., Sampaziotis, F., Rombouts, K., et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2017, 10.1136/gutjnl-2016-313598 [In press], pii: gutjnl-2016-313598.